AI assistant
Evogene Ltd. Regulatory Filings 2023
6785_rns_2023-01-24_f606fdaa-226b-46ec-8265-23b9583cdf5c.pdf
Regulatory Filings
Open in viewerOpens in your device viewer
Biomica CEO to Participate in Panel Discussion at 7 th European Annual Microbiome Movement
Rehovot, Israel – January 24, 2023 – Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), today announced its CEO and VP R&D will both be participating in 7 th Annual Microbiome Movement Drug Development Europe, taking place in London, UK, between January 31 and February 2, 2023.
The 7th Microbiome Movement – Drug Development Summit Europe aims to unite Europe's leading drug developers and microbiome experts to share their latest discoveries on microbiome functionality, translation, clinical development, biomarker discovery and manufacturing scale-up. In attendance from Biomica will be CEO Dr. Elran Haber and VP R&D Dr. Shiri Meshner.
Dr. Haber will take part in two industry panel discussions. These are entitled, "How to Turn Outstanding Microbiome Science into Effective & Efficient Products", taking place on February 1, 2023, at 9:30am GMT and "Working with Microbiome Investors", scheduled to take place later that day at 4:30pm GMT.
Dr. Meshner will be presenting on February 1, 2023, at 2:55pm, and the presentation is entitled, "Rationally Designed LBPs – From Computational & Pre-clinical Data to Clinical Studies."
Dr. Haber and Dr. Meshner will both be available for one-on-one meetings at the conference, and those interested should be in touch with the investor or public relations team.
About Biomica
Biomica is a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics utilizing a dedicated Computational Predictive Biology platform (CPB), licensed from Evogene. Biomica aims to identify and characterize disease-related microbiome entities and to develop novel therapeutics based on these understandings. The company is focused on the development of therapies for antibiotic resistant bacteria, immuno-oncology, and microbiomerelated gastrointestinal (GI) disorders. Biomica is a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN). For more information, please visit www.biomicamed.com.
Evogene Contacts:
Investor Relations
Kenny Green Email: [email protected] Tel: +1 212 378 8040
Public Relations Lital Mamon Email: [email protected] Tel: +972 8 931 2097